Breakthrough chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting that occurs despite prophylactic treatment, posing a significant challenge in cancer care. Effective management often requires a combination of pharmacological strategies tailored to individual patient needs and the emetogenic potential of the chemotherapy regimen.